Literature DB >> 19261479

Anthranilic acid based CCK1 receptor antagonists: blocking the receptor with the same 'words' of the endogenous ligand.

Lucia Lassiani1, Michela V Pavan, Federico Berti, George Kokotos, Theodoros Markidis, Laura Mennuni, Francesco Makovec, Antonio Varnavas.   

Abstract

The anthranilic acid diamides represent the more recent class of nonpeptide CCK(1) receptor antagonists. This class is characterized by the presence of anthranilic acid, used as a molecular scaffold, and two pharmacophores selected from the C-terminal tetrapeptide of CCK. The lead compound coded VL-0395, endowed with sub-micromolar affinity towards CCK(1) receptors, was characterized by the presence of Phe and 2-indole moiety at the C- and N-termini of anthranilic acid, respectively. Herein we describe the first step of the anthranilic acid C-terminal optimization using, instead of Phe, aminoacids belonging to the primary structure of CCK-8 and other not coded residues. Thus we demonstrate that the CCK(1) receptor affinity depends on the nature of the aminoacidic side chain as well as that the free carboxy group of the alpha-aminoacids is crucial for the binding. The R enantiomers of the most active compounds represent the eutomers of this class of antagonists confirming thus the stereo preference of the receptor. Moreover this SAR study demonstrates that the receptor binding pocket, that host the aminoacidic side chain, results much more tolerant respect to that accommodating the indole ring. As a result, an appropriate variation of the aminoacidic side chain could provide a better CCK(1) receptor affinity diorthosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19261479     DOI: 10.1016/j.bmc.2009.02.012

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  3 in total

1.  Nicotinamide-based diamides derivatives as potential cytotoxic agents: synthesis and biological evaluation.

Authors:  Min Peng; Liqiao Shi; Shaoyong Ke
Journal:  Chem Cent J       Date:  2017-10-24       Impact factor: 4.215

2.  Discovery of a natural product-like iNOS inhibitor by molecular docking with potential neuroprotective effects in vivo.

Authors:  Hai-Jing Zhong; Li-Juan Liu; Cheong-Meng Chong; Lihua Lu; Modi Wang; Daniel Shiu-Hin Chan; Philip Wai Hong Chan; Simon Ming-Yuen Lee; Dik-Lung Ma; Chung-Hang Leung
Journal:  PLoS One       Date:  2014-04-01       Impact factor: 3.240

3.  The Design and Development of Potent Small Molecules as Anticancer Agents Targeting EGFR TK and Tubulin Polymerization.

Authors:  Saleh Ihmaid; Hany E A Ahmed; Mohamed F Zayed
Journal:  Int J Mol Sci       Date:  2018-01-30       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.